MAVENCLAD® (cladribine) tablets PRESCRIPTIONS AND SERVICE REQUEST FORM







1 | Patient Information

Patient Name			Preferred Phone Number	Home	Work	Cell
SS #	DOB		— Okay to leave message at prefe	erred number?	Yes	No
Home Address			 Email	Preferred L	anguage	
City	State	Zip	— Preferred Method of Communi Phone Email Tex			
2 Patient Medi	ical History	/	THORE CHAIL TEX	t (opt-in below) _	Cell if not pro	vided above
Last DMD		Date of Last Dose	Concurrent Medications			
Previous MS DMDs			Allergies	No Kno	own Drug All	ergies
3 Patient Auth	orization					
3A I have read and ur	nderstand the Au	thorization to Use and Discl	ose Health and Other Personal Infor	mation and agree	e to the term	s on <u>page 3</u> .
PATIENT NAME			Authority/relationship of pers Legal Guardian Pov	onal representat wer of Attorney	tive:	
PATIENT SIGNATURE (or personal representative)		Date	_	,		
3B By checking this	s box, I confirm tha	at I have read and understand th	ne Opt-in for Marketing Text Messages	and agree to the	terms on <u>pag</u>	<u>e 3</u> .
Type of Insurance		(Please include a copy	y of both sides of the insura	nce card)		
Employer Healthcare Exchange Other:	Medicaid	Medicare No Insurance	Name of Pharmacy Benefits M	anager		
Other.			ID # Group	» #	BIN	
Primary Insurance		Cardholder	PCN Phone	: #		
ID#	Group #	Phone #	Has prior authorization (PA) be If "Yes", PA status: Approv		Yes In Progre	No ess
5 Prescriber In	formation		Preferred Pharmacy			
Prescriber Name			Office/Clinic/Institution			
Prescriber Email	Presc	riber Phone	Address			
Prescriber Fax	NPI #	+	City	State	Zip	
Tax ID #			Office Contact Name			
			Office Contact Email	Office Con	tact Phone	

MAVENCLAD® (cladribine) tablets PRESCRIPTIONS AND SERVICE REQUEST FORM

		C '	•	
M	Z I 1.	feLi	$n \Delta$	\subset
IVI	┛┕╵		\Box	O

	Send Fax 1-866-227-3243
(II)	1-866-227-3243



Patient Name	Patient DOB	Prescriber Name	Prescriber NPI #	<u></u> ∧	CANNOT PROCESS FORM WITHOUT THIS PORTION COMPLETED

6 | MAVENCLAD 10-mg tablets Prescription Information

PATIENT WEIGHT TREATMENT COURSE:		Is your patient ready to start therapy?	Yes	No
lbs kg	Year 1 Year 2	If no, what is the intended date to start therapy?		

In the tables below, check the row corresponding to the number of tablets to prescribe in the first cycle (month 1) and again in the second cycle (month 2). The weight tables below are provided for your reference.

▲ 6A | FIRST CYCLE (Month 1): Number of MAVENCLAD 10-mg tablets per cycle

Weight Range: ~lb (kg)	Day 1	Day 2	Day 3	Day 4	Day 5	Total # of Tablets Authorized in 1st Cycle (Month 1)
88 to <110 lb (40 to <50 kg)	1	1	1	1	0	4
110 to <132 lb (50 to <60 kg)	1	1	1	1	1	5
132 to <154 lb (60 to <70 kg)	2	1	1	1	1	6
154 to <176 lb (70 to <80 kg)	2	2	1	1	1	7
176 to <198 lb (80 to <90 kg)	2	2	2	1	1	8
198 to <220 lb (90 to <100 kg)	2	2	2	2	1	9
220 to <242 lb (100 to <110 kg)	2	2	2	2	2	10
≥242 lb (110 kg and above)	2	2	2	2	2	10

2242 Ib (110 kg and above)	2					10		
Please indicate DAW or substitution permitted by signing ONLY the applicable line. (Signature stamps not acceptable)								
OR								
Prescriber Signature (Dispense as written) Date Prescriber Signature (Substitution permitted) Date								
No Refill. Instructions for Use: Take by mouth daily at intervals of 24 hours approximately the same time each day per product package instructions.								

6B | SECOND CYCLE (Month 2): Number of MAVENCLAD 10-mg tablets per cycle

Weight Range: ~lb (kg)	Day 1	Day 2	Day 3	Day 4	Day 5	Total # of Tablets Authorized in 2nd Cycle (Month 2)
88 to <110 lb (40 to <50 kg)	1	1	1	1	0	4
110 to <132 lb (50 to <60 kg)	1	1	1	1	1	5
132 to <154 lb (60 to <70 kg)	2	1	1	1	1	6
154 to <176 lb (70 to <80 kg)	2	2	1	1	1	7
176 to <198 lb (80 to <90 kg)	2	2	1	1	1	7
198 to <220 lb (90 to <100 kg)	2	2	2	1	1	8
220 to <242 lb (100 to <110 kg)	2	2	2	2	1	9
≥242 lb (110 kg and above)	2	2	2	2	2	10

Please indicate DAW or substitution permitted by signing ONLY the applicable line. (Signature stamps not acceptable)

OR

Prescriber Signature (Substitution permitted)

No Refill. Instructions for Use: Take by mouth daily at intervals of 24 hours approximately the same time each day per product package instructions.

7 | Complete and Sign Statement of Medical Necessity

PRIMARY DIAGNOSIS: ICD-10 code G35

- I certify the prescribed therapy is medically necessary for the treatment of relapsing forms of multiple sclerosis, and that this information is accurate to the best of my knowledge.
- I authorize EMD Serono, Inc. to be my designated agent (1) to provide any information on this form to the insurer of the above-named patient and (2) to forward the above prescription by any method, under applicable law, to the pharmacy chosen by the above-named patient.

Λ	
4	

Prescriber's Signature:	Date:
	nas obtained HIPAA-compliant authorization from the above-named patient to disclose

following page, including assisting the patient with obtaining insurance coverage for MAVENCLAD.





Authorization to Use and Disclose Health and Other Personal Information

I authorize my treating physician(s), pharmacy(ies), health insurance company(ies), prescription drug plan(s), and other parties providing me health care or paying for my health care (collectively, "My Health Care Providers and Plans") to disclose my personal and protected health information ("Health Information") to EMD Serono, Inc. and its agents and representatives (collectively "EMD Serono"). My Health Information may include, but is not limited to, information regarding my diagnosis of and treatment for multiple sclerosis ("MS"), information included in a Prescription and Service Request Form, and any other information deemed relevant by My Health Care Providers and Plans that may be considered sensitive or specially protected by law. EMD Serono may use and further disclose my Health Information to My Health Care Providers and Plans or other third parties in order to: (1) enroll me in and administer the MS LifeLines Support Program and contact me by mail, email, or by live call at the telephone number(s) listed below, or to any future telephone number(s) provided by me; (2) conduct a benefits investigation and coordinate my insurance coverage for any prescribed EMD Serono product(s); (3) facilitate the filling of my prescription for and the delivery and administration of that product(s); (4) contact me regarding the MS LifeLines Support Program and conduct quality assurance, surveys, and other internal business activities in connection with the MS LifeLines Support Program; and (5) conduct marketing activities that includes, but is not limited to, providing me with educational and promotional materials, information, special offers, and services related to my therapy or my medical condition and/or to conduct market research activities that includes contacting me to participate in focus groups, surveys, or interviews that may be funded or sent by EMD Serono, a MS LifeLines Support Program, or an EMD Serono affiliate.

I understand that once my information is disclosed pursuant to this authorization, it may no longer be protected by federal privacy laws (eg, the Health Insurance Portability and Accountability Act [HIPAA]) or state privacy laws and may be further disclosed to others. However, I understand that EMD Serono will not release my personally identifiable information to any party, except as provided in this authorization or as permitted by applicable law, without first obtaining my (or my authorized representative's) separate written consent.

I understand that I may refuse to sign this authorization and such refusal will not affect my ability to receive any EMD Serono product, my treatment, payment for treatment, eligibility for or enrollment in health benefits, but it will limit my ability to receive MS LifeLines Support Program services. I understand that this authorization will remain in effect for 10 years, or such shorter period as may be required by state law, from the date of my signature unless I revoke it earlier by contacting EMD Serono in writing at EMD Serono & MS LifeLines, One Technology Place, Rockland, MA 02370. If I revoke this authorization, My Health Care Providers and Plans will stop disclosing this information to EMD Serono, and EMD Serono will stop using and disclosing my information, as soon as possible, but the revocation will not affect prior use or disclosure of my information in reliance on this authorization.

I understand that certain of My Health Care Providers and Plans may receive compensation in exchange for their disclosure of my information to EMD Serono. I also understand that I have the right to receive a signed copy of this authorization.

To authorize your consent, please complete Step 3: Patient Authorization on page 1, including signature line.

Opt-In for Automated Marketing Text Messages

I authorize EMD Serono, Inc. (or its agents), to send marketing text messages to the cell phone number(s) listed (or to any future telephone number(s) provided by me to EMD Serono, Inc. or its agents) using an automatic telephone dialing system on a recurring basis. This consent also enables EMD Serono to contact me by text message to provide me with MS LifeLines Support Program services. Signing this consent is not a condition of participating in the MS LifeLines Support Program or purchasing products, goods, or services from EMD Serono. I understand that my mobile phone service provider may charge me fees for texts sent to me, and I agree that EMD Serono will have no liability for the cost of any such calls or texts. At any time, I may withdraw my consent to receive text messages by replying "STOP" via return text message or contacting EMD Serono in writing at EMD Serono & MS LifeLines, One Technology Place, Rockland, MA 02370.

To authorize your consent, please check the box listed in Step 3: Patient Authorization on page 1.